Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • 2Q Stock Wrap-Up: Large and in charge

    Winners, losers in biotech stock tiers in 2Q14

    Following a first quarter that saw all market cap segments gain ground, only the large caps finished in the black in 2Q14.

    Published on 7/14/2014
  • States' rights

    As right-to-try landscape expands in U.S., so does debate on laws' effect

    State right-to-try laws reflect deep dissatisfaction with the pace of drug development, but industry and some patient advocates don't think they'll work.

    Published on 6/30/2014
  • Box: Neuralstem's plans

    States' rights Neuralstem's plans At least one company has announced its intention to make a product available to patients under state right-to-try laws. Neuralstem Inc. President and CEO Richard Garr told …

    Published on 6/30/2014
  • Accelerating adaptation

    Why EMA has been able to get adaptive licensing off the ground ahead of FDA

    EMA's adaptive licensing pilot places Europe ahead of the U.S., largely because stricter controls on prescribing in Europe preclude the concerns that have stalled FDA's special medical use pathway.

    Published on 6/23/2014
  • Nucleotide arms race

    Idenix nucleotide analog fills Merck gap in race for pan-genotype HCV regimen

    The Idenix acquisition fills a gap in Merck's HCV tool kit with a nuc that could allow the pharma to develop a pan-genotypic HCV regimen that would treat all patients.

    Published on 6/16/2014
  • Box: Sussing safety

    Nucleotide arms race Sussing safety Idenix Pharmaceuticals Inc. had faced safety problems with more than one nucleotide analog before August 2012, when Bristol-Myers Squibb Co. reported heart and kidney toxicity, …

    Published on 6/16/2014
  • Figure: Idenix chronicles

    Nucleotide arms race Idenix chronicles Shares of Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) more than tripled last week after Merck & Co. Inc. (NYSE:MRK) said it will acquire Idenix for $24.50 per share in cash, or …

    Published on 6/16/2014
  • Box: Marked response?

    Advantage, Merck Marked response? Over half of tumors express PD-L1, but it's not clear whether the marker can be used to make treatment decisions. At the American Society of Clinical Oncology (ASCO) meeting, four …

    Published on 6/9/2014
  • Table: PD-1 comps in melanoma

    Advantage, Merck PD-1 comps in melanoma Early data presented at ASCO suggest the lead mAbs against PD-1 receptor (PDCD1; PD-1; CD279) from Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co. Inc. (NYSE:MRK) could …

    Published on 6/9/2014
  • Table: PD-1/PD-L1 comps in NSCLC

    Advantage, Merck PD-1/PD-L1 comps in NSCLC While early data presented at ASCO in non-small cell lung cancer (NSCLC) could appear to give nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) an efficacy advantage over …

    Published on 6/9/2014
  • Bladder breakthrough

    Genentech anti-PD-L1 immunotherapy could be 1st bladder cancer drug in 20 years

    Unlike its peers, Genentech has chosen metastatic bladder cancer as the lead indication for its anti-PD-L1 mAb. Based on Phase I data at ASCO, uptake in this underserved population could be swift.

    Published on 6/9/2014
  • Advantage, Merck

    How Merck may have advantage over BMS, AZ with PD-1/PD-L1 immunotherapies

    Data at ASCO show the three leading PD-1 and PD-L1 inhibitors have similar efficacy. Until more data are in, Merck looks to have the advantage based on dosing convenience in melanoma and toxicity in NSCLC.

    Published on 6/9/2014
  • Reforming oncology

    ASCO, payers taking different paths to cancer payment reform

    ASCO has made drug prices and value a centerpiece of its annual meeting, but private payers are coming up with more drug-centric approaches to cancer payment reform.

    Published on 6/2/2014
  • Box: Stumped

    Reforming oncology Stumped Jeffery Ward, an oncologist at Swedish Cancer Institute and chair of the ASCO payment reform working group, said the task force considered alternatives to buy-and-bill but couldn't arrive …

    Published on 6/2/2014
  • Europe's Iceberg 2014: Premier League teams

    BioCentury's 12th Iceberg survey: Top European companies need U.S. investors

    BioCentury's 12th annual European Iceberg survey finds the funding gap narrowing between the U.S. and European Premier League clubs. But to avoid relegation, top companies will need to aggressively pursue U.S. investors…

    Published on 5/26/2014
  • Figure: Clinical rationing

    Divergent appetites Clinical rationing Venture investors made triple-digit increases in funding for private companies with compounds in preclinical development or marketed products in 2013, while clinical stage …

    Published on 5/26/2014
  • Figure: Europe's total demand

    Divergent appetites Europe's total demand BioCentury projects that private and public European biotech companies with compounds in the clinic and beyond will need $5.7 billion over the next three years to keep their…

    Published on 5/26/2014
  • Figure: Private demand

    Divergent appetites Private demand Private European biotechs in the clinic and beyond will need an estimated $5.1 billion to support operations to the end of 2016, compared with a three-year estimate of $4.6 billion…

    Published on 5/26/2014
  • Figure: Public demand

    Divergent appetites Public demand Unprofitable public European biotechs in the clinic and beyond will need an estimated $585.8 million to support operations to the end of 2016 - the second lowest three-year demand …

    Published on 5/26/2014
  • Table: New funds

    Divergent appetites New funds Since the start of 2013, at least 15 life science funds with a European presence are raising or have raised a total of more than $4.5 billion. Deerfield Private Design Fund III tops the…

    Published on 5/26/2014
  • Box: The Cellectis experience

    Premier League teams The Cellectis experience When courting potential investors, the contents of the presentation - and the audience - can make all the difference. Such was the experience of Cellectis S.A. …

    Published on 5/26/2014
  • Figure: Capital rationing

    Premier League teams Capital rationing The top decile of private European money raisers elevated their game in 2013, averaging $63.3 million vs. $49.7 million in 2012, and better than matching the average of $62.3 …

    Published on 5/26/2014
  • Figure: EU vs. U.S. private raised

    Premier League teams EU vs. U.S. private raised Money raised by private European biotechs was up 48% to $1.7 billion in 2013 from $1.2 billion in 2012, while the U.S. saw a 17% decline to $3.9 billion from $4.7 …

    Published on 5/26/2014
  • Figure: EU vs. U.S. public raised

    Premier League teams EU vs. U.S. public raised Excluding debt, the top figure shows public biotechs in Europe increased their equity fundraising by 60% to $1.8 billion from 2012 vs. a 41% increase in the U.S. to $11…

    Published on 5/26/2014
  • Figure: Global competition for capital

    Premier League teams Global competition for capital Both Europe and the U.S. saw declines in total money raised from 2012 to 2013. However, excluding $1 billion-plus debt financings, the total raised in each region …

    Published on 5/26/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993